Literature DB >> 22378673

Mitochondrial disease in 22q13 duplication syndrome.

Richard E Frye1.   

Abstract

Both copy number changes in the 22q13 region and mitochondrial disease have been associated with autism spectrum disorder. In this report, for the first time, a girl with autism spectrum disorder is described who exhibits both mitochondrial disease and a 22q13.1-33 duplication. This child demonstrated hypotonia, developmental delays, growth deficiency, microcephaly, dysmorphic facial features, and white matter abnormalities, consistent with previous cases of 22q13 region duplication. The patient also demonstrated a unique pattern of electron transport chain abnormalities with marked decreases in complex II and II/III in fibroblasts and complex I/III and II/III in muscle tissue. The 22q13.1-33 region contains 6 genes associated with mitochondrial function. Thus, disruption of this chromosomal region could cause many of the clinical findings in this child through disruption of mitochondrial function. Therefore, a mitochondrial workup should be considered in individuals with copy number changes within the 22q13 region, such as those with Phelan-McDermid syndrome.

Entities:  

Mesh:

Year:  2012        PMID: 22378673     DOI: 10.1177/0883073811429858

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  12 in total

Review 1.  Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.

Authors:  Dmitriy M Niyazov; Stephan G Kahler; Richard E Frye
Journal:  Mol Syndromol       Date:  2016-06-03

2.  Array-based comparative genomic hybridization in 190 Korean patients with developmental delay and/or intellectual disability: a single tertiary care university center study.

Authors:  Cha Gon Lee; Sang-Jin Park; Jun-No Yun; Jung Min Ko; Hyon-Ju Kim; Shin-Young Yim; Young Bae Sohn
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

Review 3.  Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure.

Authors:  Sarah Wong; Cecilia Giulivi
Journal:  CNS Neurol Disord Drug Targets       Date:  2016       Impact factor: 4.388

4.  Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome.

Authors:  Richard E Frye; Shannon Rose; John Slattery; Derrick F MacFabe
Journal:  Microb Ecol Health Dis       Date:  2015-05-07

Review 5.  Neuropathological Mechanisms of Seizures in Autism Spectrum Disorder.

Authors:  Richard E Frye; Manuel F Casanova; S Hossein Fatemi; Timothy D Folsom; Teri J Reutiman; Gregory L Brown; Stephen M Edelson; John C Slattery; James B Adams
Journal:  Front Neurosci       Date:  2016-05-10       Impact factor: 4.677

Review 6.  Treatments for biomedical abnormalities associated with autism spectrum disorder.

Authors:  Richard Eugene Frye; Daniel A Rossignol
Journal:  Front Pediatr       Date:  2014-06-27       Impact factor: 3.418

7.  Mitochondrial Dysfunction may explain symptom variation in Phelan-McDermid Syndrome.

Authors:  Richard E Frye; Devin Cox; John Slattery; Marie Tippett; Stephen Kahler; Doreen Granpeesheh; Shirish Damle; Agustin Legido; Michael J Goldenthal
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

Review 8.  Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes.

Authors:  Richard E Frye; Daniel A Rossignol
Journal:  Clin Med Insights Pediatr       Date:  2016-06-15

9.  Autistic Siblings with Novel Mutations in Two Different Genes: Insight for Genetic Workups of Autistic Siblings and Connection to Mitochondrial Dysfunction.

Authors:  Barrett J Burger; Shannon Rose; Sirish C Bennuri; Pritmohinder S Gill; Marie L Tippett; Leanna Delhey; Stepan Melnyk; Richard E Frye
Journal:  Front Pediatr       Date:  2017-10-12       Impact factor: 3.418

Review 10.  Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder.

Authors:  Shannon Rose; Dmitriy M Niyazov; Daniel A Rossignol; Michael Goldenthal; Stephen G Kahler; Richard E Frye
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.